title: Current oral agents for type 2 diabetes. Many options, but which to choose when?
abstract: Increasingly, type 2 diabetes takes a toll on public health and healthcare costs in the United States. Although the remedy for this growing problem is very complex, two critical components of its control are prevention and effective therapy. Progress in diabetes prevention is likely to take decades. But fortunately, growth in our understanding of what occurs in this chronic disease has led to advances in the pharmacologic options aimed at decreasing hyperglycemia, the main clinically measurable metabolic consequence of diabetes. In this article, Drs Ahmann and Riddle provide an overview of the oral agents now available for the treatment of diabetes and discuss the clinical factors that help determine when to use which medication and what outcome to expect.
authors.affiliation: Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University School of Medicine, 3181 SW Sam Jackson Park Rd, OP05, Portland, OR 97201-3098, USA. ahmanna@ohsu.edu
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Ahmann
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Riddle
mesh_terms: D002219:Carbamates / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination; D006026:Glycoside Hydrolases / Q000037:antagonists & inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D014157:Transcription Factors / Q000819:agonists
chemical_list: D002219:Carbamates; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D010880:Piperidines; D018160:Receptors, Cytoplasmic and Nuclear; D013453:Sulfonylurea Compounds; D014157:Transcription Factors; D000077715:Nateglinide; D010649:Phenylalanine; C072379:repaglinide; D008687:Metformin; D006026:Glycoside Hydrolases; C096734:alpha-glucuronidase